Attralus Closes $56 Million Financing

Attralus Closes $56 Million Financing

PDF Version Proceeds intended to advance clinical pipeline of transformational pan-amyloid removal (PAR) therapeutic candidates Financing led by Alpha Wave Global and also included Bristol Myers Squibb (BMY) SAN FRANCISCO – February 06, 2024 – Attralus, Inc., a...
Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology

PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs. AT-01 demonstrated to be highly accurate, with 100% sensitivity for detection of cardiac amyloid, across three independent...